ArticleJournal of pharmacy & bioallied sciences2025
Study of Diabetes and Extrapulmonary Tuberculosis (Cervical Lymphoadenopathy, Skin TB, CNS TB, Plueural Tubercular Effusion).
Article in Journal of pharmacy & bioallied sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Study to Asses Effects of Diabetes Mellitus on Treatment Outcome of Tuberculosis Patients.Journal of pharmacy & bioallied sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetes mellitus (DM) is a significant risk factor for tuberculosis (TB), increasing susceptibility to both pulmonary and extrapulmonary TB (EPTB). Extrapulmonary manifestations, including cervical lymphadenopathy, cutaneous tuberculosis (TB), central nervous system (CNS) TB, and pleural tubercular effusion, pose diagnostic and therapeutic challenges. Materials and Methods: A hospital-based observational study was conducted on 150 diabetic patients diagnosed with EPTB. The study population was divided into four groups based on the site of infection: cervical lymphadenopathy ( Results: Among the study population, 65% were male, and 35% were female, with a mean age of 52.4 ± 8.7 years. Poor glycemic control (HbA1c >8.0%) was observed in 60% of the patients. The most prevalent manifestation was cervical lymphadenopathy (33.3%), followed by cutaneous TB (26.7%), CNS TB (20%), and pleural tubercular effusion (20%)**. Treatment success was noted in 78% of cases, while 15% showed partial response, and 7% had poor outcomes. Diabetic patients with poor glycemic control had significantly higher treatment failure rates ( Conclusion: Diabetes increases the risk of extrapulmonary TB, with cervical lymphadenopathy being the most common presentation. Poor glycemic control adversely affects treatment outcomes. Early diagnosis and strict glycemic management are essential for improving prognosis in diabetic patients with EPTB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.